Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry

EuroIntervention. 2023 Mar 20;18(15):1266-1268. doi: 10.4244/EIJ-D-22-00594.

Authors

Giuseppe Gargiulo¹, Alessandra Marenna¹, Luca Sperandeo¹, Lina Manzi¹, Marisa Avvedimento¹, Fiorenzo Simonetti¹, Mario Enrico Canonico¹, Roberta Paolillo¹, Alessandra Spinelli¹, Francesco Borgia¹, Luigi Diserafino¹, Anna Franzone¹, Eugenio Stabile², Raffaele Piccolo¹, Plinio Cirillo¹, Marco Valgimigli³, Giovanni Esposito¹

Affiliations

¹ Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy.
² Cardiovascular Department, Azienda Ospedaliera Regionale "San Carlo," Potenza, Italy.
³ Cardiocentro Institute, Ente Ospedaliero Cantonale, Università della Svizzera Italiana (USI), Lugano, Switzerland.

No abstract available

MeSH terms

Adenosine Monophosphate / pharmacology
Adenosine Monophosphate / therapeutic use
Humans
Percutaneous Coronary Intervention*
Platelet Aggregation Inhibitors / pharmacology
Platelet Aggregation Inhibitors / therapeutic use
Purinergic P2Y Receptor Antagonists
Registries
Treatment Outcome

Substances

cangrelor
Adenosine Monophosphate
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists